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S208 Oral Presentationsdespite persistently elevated plasma BAFF levels. High BAFF to B cell
ratios are associatedwith increased proportions of activated peripheral
B cells. B cell reconstitution occurs during constant exposure to allo-
and neo-autoantigens after HSCT. We hypothesize that failure to
delete these potentially pathologic cells in cGVHDisdue toBAFFsig-
naling. We recently found that B cells from patients with active
cGVHD have decreased pro-apoptotic Bim (Wooten et al ASH
2010, Abstract 216). BAFF is known to enhance B cell survival by
counteracting pro-apoptotic Bim, but upstream BAFF-driven survival
signaling in cGVHD (and other diseases) remains undetermined.
HSCT patients who were .12 months post-HSCT, not receiving
high dose steroid, with or without active cGVHD were studied. We
first examined apoptotic rates by flow cytometric analysis of 14 freshly
isolated (to .95% CD19+ purity) B cell samples cultured over time.
Patients with active cGVHD (n 5 4) had significantly decreased
apoptosis at 48 hours, compared to either patients who had never de-
velopeddisease (n55)or tohealthy controls (n5 5) (p\0.005).While
BAFF-driven B cell survival can bemodulated by altered expression of
apoptotic factors, it can also be affected by cellular metabolic fitness.
To examine B cell metabolic fitness wemeasured cellular protein con-
tent in freshly purified B cells from 28 HSCT patients. Significantly
increased B cell protein content was found in active cGVHD patients
(n 5 10) compared to patients who never developed disease (n 5 7)
(p\0.005). Increased protein content was also found in patients who
had inactive disease (n 5 11) although this did not reach statistical
significance. Since BAFF is known to induce metabolic fitness via
phosphorylation of AKT in murine B cells, we examined AKT
activation by immunoblotting freshly isolated B cell lysates from 18
HSCT patients. B cells from patients with active cGVHD (n 5 8)
had significantly increased phosphorylated AKT (pS743 normalized
to total AKT) compared to patients with inactive disease (n 5 7)
(p\0.005). By contrast, no difference in Erk phosphorylation was
found between groups. Our study reveals that B cells in cGVHD
have increased survival due to increased AKT pathway driven
metabolic fitness. Thus, we provide rationale for study of small
molecule inhibitors of the AKT pathway in cGVHD patients.
Table. B cells from patients with cGVHD have increased cel-
lular protein content and AKTactivation
Cellular Protein Normalized One-waycGVHD
GroupContent (mg protein /
1 x 10^6 cells)
Mean +/- SEOne-way
ANOVA,
versus NopAKT (pS743 /
AKT)
Mean +/- SEANOVA,
versus
InactiveNo 35.4 +/- 5.4, n 5 7 - 0.16 +/- 0.09, n 5 3 NSInactive 56.9 +/- 5.2, n 5 11 NS 0.05 +/- 0.02, n 5 7 -Active 75.8 +/- 9, n 5 10 p < 0.005 0.63 +/- 0.15, n 5 8 p < 0.005NS; Not significant.16
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Background: ScGVHD is characterized by progressive fibrosis of
the dermis and subcutis and develops in 4-13% of patients with
cGVHD. The clinical risk factors and mechanisms responsible for
ScGVHD remain unclear; however, the profibrogenic platelet-
derived growth factor (PDGF) and transforming growth factor-
b (TGF-b) signaling pathways have been implicated. Imatinib
mesylate is a tyrosine kinase inhibitor that has activity against both
PDGFR and TGF-b as well as a well-established safety profile for
the treatment of chronic myelogenous leukemia.
Methods: Eligible patients had ScGVHD limiting range-of-motion
(ROM) of at least 1 joint by .25%. Initially, patients were given
400mg (pediatric 260mg/m2) imatinib daily (cohort 1), with dose
reduction allowed for toxicity. Due to a high incidence of adverseeffects (AEs) and subsequent dose reduction, the study was amended
to start 100mg with escalation to 200mg daily at 1 month. The 6
month primary endpoint was based on percent improvement of the
deficit compared to baseline at 1-3 target joints: partial response
(PR) 5 increase of .25%; progressive disease (PD) 5 decrease of
.25%, or .1 steroid pulse per 3-month period; stable disease
(SD) 5 all other. Secondary endpoints included toxicity; multi-mo-
dality skin assessments (MRI, skin score, and patient-reported mea-
sures); quality of life and functional measures; steady state serum
drug concentrations (cohort 2); and response of other cGVHD-af-
fected organs.
Results: Twenty patients were enrolled (8 cohort 1, 12 cohort 2).
Two patients had PD; 5 PR; 7 SD; and 6 were non-evaluable
(Table 1). Of 11/14 (78.6%) patients with any ROM improvement,
the average gain in ROMwas 31%. No significant improvement was
seen in other cGVHD manifestations. Frequent AEs included hy-
pophosphatemia, GI upset, fatigue, muscle cramping and pain.
Other clinically significant AEs were tinnitus (n5 4) and pulmonary
edema requiring hospitalization (n 5 2). Steady state serum con-
centrations in cohort 2 (200mg daily) ranged from 592-2255ng/mL
(mean 1157ng/mL), which is within the inhibitory range of imatinib
on PDGFR.
Table 1. Patient Responses
% changePatient
Number Age GenderTime from
cGVHD
Dx (mos) pBaseline
ROM %
redictedin deficit
from baseline
at 6 mos Response Final Dose1 56 Male 48.5 37% Off-withdrawal N/A N/A2 60 Male 48.2 56% 94% PR 300mg3 10 Female 39.1 73% Off- 3 mos PD PD N/A4 52 Female 28.9 7% Off- toxicity N/A N/A5 30 Male 87.0 34% Off - withdrawal N/A N/A6 51 Male 88.1 47% Off - withdrawal N/A N/A7 55 Female 42.5 61% 35% PR 200 mg8 58 Male 39.1 35% 16% SD 200 mg9 60 Male 79.4 42% Off - withdrawal N/A N/A10 53 Male 20.3 -7% 21% SD 200 mg11 28 Female 15.8 56% Off - cancer
relapse
N/A N/A12 56 Male 80.3 37% 16% SD 100 mg13 34 Female 21.4 27% 61% PR 200 mg14 46 Male 40.6 32% 27% PR 200 mg15 55 Male 33.5 22% 22% SD 200 mg16 55 Male 4.8 71% 3% SD 200 mg17 7 Female 25.4 64% -25% SD 100 mg (peds)18 21 Male 58.9 54% -2% SD 200 mg19 48 Male 112.9 33% 31% PR 200 mg20 18 Male 35.0 -5% 15% SD 200 mgcGVHD 5 chronic graft versus host disease, Dx 5 diagnosis, mo 5
month, ROM5 range of motion, PD5 progressive disease, PR5 partial
response, SD 5 stable disease, N/A 5 not assessed.
Conclusions:Treatment with imatinib mesylate for 6 months led to
improved ROM in most patients. This data suggests that low-dose
imatinib therapy has efficacy for ScGVHD; however, despite serum
drug concentrations in the expected range for the doses prescribed,
tolerability was a significant limitation for the use of imatinib mesy-
late in patients with ScGVHD.
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Graft-versus-host disease (GvHD) is a serious challenge to the
success of hematopoietic stem cell transplantation. The cytokine
